Therapy News and Research

RSS

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer's disease (AD) and related disorders are currently being diagnosed and treated.

4 Jun 2010

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.

4 Jun 2010

GHP selects MirixaPro web-based clinical platform to support delivery of MTM services

The Geisinger Health Plan, a regional provider of health benefits to almost 250,000 members in Pennsylvania, has selected Mirixa Corporation's MirixaPro web-based clinical platform to support the delivery of medication therapy management services to its Medicare Part D members.

4 Jun 2010

New autism early intervention centers promised for Mackay and Bundaberg

The Queensland Government has announced $1 million a year over three years for new autism centers in Bundaberg and Mackay. These will provide care and also early intervention services to the substantial number of autistic children in the region.

3 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.

3 Jun 2010

Discovery reveals a new approach to target cancer

Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.

3 Jun 2010

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

3 Jun 2010

New approach to treat RA can change lives of millions of patients: Research

Portuguese scientists have just published a revolutionary new approach to treat rheumatoid arthritis (RA) which, if translated to humans, can change the way we treat autoimmunity (and so diseases like RA but also diabetes and MS) and, with it, the lives of millions of patients.

3 Jun 2010

Researchers identify new therapeutic target for cognitive decline

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning.

3 Jun 2010

Research may yield new urine test to diagnose autism

Children with autism have a different chemical fingerprint in their urine than non-autistic children, according to new research published tomorrow in the print edition of the Journal of Proteome Research.

3 Jun 2010

Medtronic DBS Therapy improves motor function in patients with advanced Parkinson's disease: Study

In the largest, randomized, controlled study of deep brain stimulation for Parkinson's disease, Medtronic DBS Therapy was shown to improve motor function for up to two years in patients with advanced Parkinson's disease, showing equally strong efficacy for the two most common surgical targets used for the therapy.

3 Jun 2010

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

In the largest study to date of a rare and deadly form of bladder cancer, researchers at Henry Ford Hospital in Detroit found radiation therapy may not improve a patient's chances for survival.

3 Jun 2010

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

At the annual meeting of the American Urological Association, data using the Nanosphere Verisens™ ultra-sensitive PSA assay (research use only) will be highlighted as one of less than 40 abstracts that were singled out by the Association for a special session for journalists.

3 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

3 Jun 2010

PMRT increases breast cancer patients' five-year overall survival by almost 50%: Study

Postmastectomy radiation therapy for some breast cancer patients can reduce their risk of recurrence by almost 30 percent and increase their five-year overall survival by almost 50 percent, according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.

3 Jun 2010

Discovery provides new therapeutic target to prevent brain function loss

3 Jun 2010

Light therapy may be alternative treatment for prostate cancer

Cliff Berkman is working on a better way—one that specifically targets prostate cancer cells and causes a type of natural death that spares surrounding tissues from damage.

3 Jun 2010

Therapy News and Research

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

GHP selects MirixaPro web-based clinical platform to support delivery of MTM services

New autism early intervention centers promised for Mackay and Bundaberg

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Discovery reveals a new approach to target cancer

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

New approach to treat RA can change lives of millions of patients: Research

Researchers identify new therapeutic target for cognitive decline

Research may yield new urine test to diagnose autism

Medtronic DBS Therapy improves motor function in patients with advanced Parkinson's disease: Study

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

PMRT increases breast cancer patients' five-year overall survival by almost 50%: Study

Discovery provides new therapeutic target to prevent brain function loss

Light therapy may be alternative treatment for prostate cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News